This website uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Further information

COVIPEDIA
Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Muller MA, Drosten C, Pohlmann S
The recent emergence of the novel, pathogenic SARS-coronavirus 2 (SARS-CoV-2) in China and its rapid national and international spread pose a global health emergency. Cell entry of coronaviruses depends on binding of the viral spike (S) proteins to cellular receptors and on S protein priming by host cell proteases. Unravelling which cellular factors are used by SARS-CoV-2 for entry might provide insights into viral transmission and reveal therapeutic targets. Here, we demonstrate that SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming. A TMPRSS2 inhibitor approved for clinical use blocked entry and might constitute a treatment option. Finally, we show that the sera from convalescent SARS patients cross-neutralized SARS-2-S-driven entry. Our results reveal important commonalities between SARS-CoV-2 and SARS-CoV infection and identify a potential target for antiviral intervention.
07/03/2020
32142651
Cell (IF: 38.637 / Quartile: 1)
WOS Cites: 3638
SemanticScholar Cites: 6845
SemanticScholar Citation Velocity: 2575
SemanticScholar Influential Citation Count: 664
Only annotations in title abstract:
YES

Data Sources

IMIB-Arrixaca

Address

Biomedical Informatics & Bioinformatics Platform
Institute for Bio-health Research of Murcia (IMIB-Arrixaca)
Carretera Buenavista s/n, 30120
El Palmar, Murcia, Spain

Phones

+34 968885229
+34 968885239
+34 968885249